Integra Lifesciences Holdings (IART) Non-Current Debt (2009 - 2026)

Integra Lifesciences Holdings has disclosed Non-Current Debt across 18 years of filings, most recently posting $1.7 billion for Q2 2026.

• In Q2 2026, Non-Current Debt rose 55.27% year-over-year to $1.7 billion; the TTM figure through Jun 2026 stood at $1.7 billion (up 55.27% YoY), while the FY2025 annual figure was $1.7 billion, up 58.98% from the prior year.
• Non-Current Debt came in at $1.7 billion for Q2 2026 at Integra Lifesciences Holdings, down from $1.8 billion in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $1.8 billion in Q1 2026 to a low of $733.1 million in Q4 2022.
• Average Non-Current Debt over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2024.
• Year-over-year, Non-Current Debt retreated 11.05% in 2022 and jumped 58.98% in 2025.
• Over 5 years, Non-Current Debt stood at $733.1 million in 2022, then climbed by 12.61% to $825.6 million in 2023, then soared by 31.78% to $1.1 billion in 2024, then soared by 58.98% to $1.7 billion in 2025, then rose by 0.38% to $1.7 billion in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $1.7 billion in Q2 2026, $1.8 billion in Q1 2026, and $1.7 billion in Q4 2025.